Lexicon Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Lexicon Pharmaceuticals, Inc.

Dec-10	Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 LXRX GlobeNewswire
Dec-05	Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum LXRX GlobeNewswire
Nov-25	Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences LXRX GlobeNewswire
Nov-11	Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference LXRX GlobeNewswire
Nov-08	Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 LXRX GlobeNewswire
Nov-06	Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates LXRX GlobeNewswire
Nov-04	Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans LXRX GlobeNewswire
Oct-30	Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 LXRX GlobeNewswire
Oct-14	Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit LXRX GlobeNewswire
Oct-08	Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain LXRX GlobeNewswire
Sep-22	Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes LXRX GlobeNewswire
Sep-17	Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings LXRX GlobeNewswire
Sep-11	Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings LXRX GlobeNewswire
Sep-08	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes LXRX GlobeNewswire
Sep-04	Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 LXRX GlobeNewswire
Sep-03	Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 LXRX GlobeNewswire
Sep-02	Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress LXRX GlobeNewswire
Aug-27	Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences LXRX GlobeNewswire
Aug-06	Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates LXRX GlobeNewswire
Jul-31	Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement LXRX GlobeNewswire
Jul-23	Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 LXRX GlobeNewswire
Jul-18	Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) LXRX GlobeNewswire
Jun-23	Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) LXRX GlobeNewswire
Jun-18	Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) LXRX GlobeNewswire
May-29	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference LXRX GlobeNewswire
May-19	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology LXRX GlobeNewswire
May-13	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates LXRX GlobeNewswire
May-06	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference LXRX GlobeNewswire
May-06	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 LXRX GlobeNewswire

Lexicon Pharmaceuticals, Inc.

Recent Articles by Lexicon Pharmaceuticals, Inc.

Upgrade your FINVIZ experience